Rallybio Corp

NASDAQ:RLYB 4:00:00 PM EDT

1.13

+0.03 (+2.73%)

7:20:44 PM EDT: $1.15 +0.02 (+1.77%)

Market Cap (Intraday)	48.16M
Current PE	N/A
Forward PE	N/A
2yr Forward PE	N/A

See more stats

Estimates Current Quarter

Revenue	$0.1 Million
Adjusted EPS	-$0.35

See more estimates

10-Day MA	$1.12
50-Day MA	$1.22
200-Day MA	$1.69

See more pivots

Rallybio Corp Stock, NASDAQ:RLYB

234 Church Street, Suite 1020, New Haven, Connecticut 06510

United States of America

Phone: +1.203.859.3820

Number of Employees: 43

http://www.rallybio.com

Description

Rallybio Corp. engages in the identification, research and development, and manufacture of clinical biotechnology products and therapies for severe and rare diseases. Its product candidates focus on the areas of fetal and neonatal disorders, hematology, immuno-inflammation, and metabolic disease. The company was founded by Martin W. Mackay, Stephen Uden, and Jeffrey M. Fryer in January 2018 and is headquartered in New Haven, CT.